TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05181384

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: isolated pelvic floor muscles training
Description: isolated pelvic floor muscles training was emphasized, consisting of both quick and sustained contractions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: isolated pelvic floor muscles training
Description: isolated pelvic floor muscles training was emphasized, consisting of both quick and sustained contractions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: comprehensive stabilization exercise program
Description: incorporated the contraction of PFMs with other spinal or extremity muscles

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: comprehensive stabilization exercise program
Description: incorporated the contraction of PFMs with other spinal or extremity muscles

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: education of pelvic girdle
Description: educational session includes pelvic anatomy, mechanism of and risk factors for PPGP, and proper posture or body mechanism

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: education of pelvic girdle
Description: educational session includes pelvic anatomy, mechanism of and risk factors for PPGP, and proper posture or body mechanism

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: education of pelvic girdle
Description: educational session includes pelvic anatomy, mechanism of and risk factors for PPGP, and proper posture or body mechanism
Study: NCT02738515

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.75 % Boric Acid
Description: After Scaling and Root Planing placement of 0.75% Boric Acid gel in Mandibular degree 2 Furcation defect.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: After Scaling and Root Planing placement of Placebo gel in Mandibular degree 2 Furcation defect.
Study: NCT01761188

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ablation
Description: electrophysiology substrate mapping is the critical difference between both groups

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ablation
Description: electrophysiology substrate mapping is the critical difference between both groups
Study: NCT01618591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose rifaximin 1650 mg
Description: Rifaximin 1650 mg as a single dose plus loperamide 4 mg initially followed by 2 mg after each unformed stool, not to exceed 16 mg/day for 2 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose azithromycin 500 mg
Description: Azithromycin 500 mg as a single dose plus loperamide 4 mg initially followed by 2 mg after each unformed stool, not to exceed 16 mg/day for 2 days
Study: NCT03590860

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by SC injection
Study: NCT00609622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib
Description: Sunitinib: 37.5 mg/day, oral, administered on an outpatient basis for 4 weeks on, 2 weeks off (Schedule 4/2).
Study: NCT04049227

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo standard of care hysterectomy
Study: NCT00594724

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI
Description: Adaptation Using Functional Magnetic Resonance Imaging and Diffusion Tensor Imaging
Study: NCT02483871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Study: NCT01618591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose levofloxacin 500 mg
Description: Levofloxacin 500 mg as a single dose plus loperamide 4 mg initially followed by 2 mg after each unformed stool, not to exceed 16 mg/day for 2 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose azithromycin 1000 mg plus loperamide
Description: Azithromycin 1000 mg as a single dose plus loperamide 4 mg initially followed by 2 mg after each unformed stool, not to exceed 16 mg/day for 2 days
Study: NCT00609622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6
Description: FOLFOX will be administered every 2 weeks, using the modified FOLFOX6 (mFOLFOX6) regimen, consisting of: - oxaliplatin 85 mg/ m\^2 + leucovorin 400 mg/ m\^2 (or 200 mg/ m\^2 levo-leucovorin) as a 2-hr IV infusion followed by 5-fluorouracil 400 mg/ m\^2 IV bolus on day 1 and 5-fluorouracil 2400 mg/ m\^2 IV infusion over 46 hours on Days 1 and 2 of each 2 week cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab
Description: Bevacizumab: 5 mg/kg, IV infusion, every 2 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFOLFOX6
Description: FOLFOX will be administered every 2 weeks, using the modified FOLFOX6 (mFOLFOX6) regimen, consisting of: - oxaliplatin 85 mg/ m\^2 + leucovorin 400 mg/ m\^2 (or 200 mg/ m\^2 levo-leucovorin) as a 2-hr IV infusion followed by 5-fluorouracil 400 mg/ m\^2 IV bolus on day 1 and 5-fluorouracil 2400 mg/ m\^2 IV infusion over 46 hours on Days 1 and 2 of each 2 week cycle
Study: NCT01618591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose azithromycin 1000 mg plus placebo
Description: Azithromycin 1000 mg as a single dose and placebo in lieu of loperamide
Study: NCT03974906

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Applying goal-directed fluid therapy by continuous hemodynamic monitoring system (LiDCO）
Description: Applying continuous hemodynamic monitoring system ( LiDCO) to monitor Stroke Volume Variation and Cardiac Output and further manage intra-operative fluid therapy.
Study: NCT05527522

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: nutritional and educational intervention
Description: individualized diet plus educational intervention with/without nutritional supplements

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: standard practice
Description: The patients received the usual treatment and clinical practice
Study: NCT00886990

Intervention type: DRUG
Intervention: ritonavir-boosted PI-based second line treatments
Description: single PI boosted by low dose ritonavir
Study: NCT05527522

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard practice
Description: The patients received the usual treatment and clinical practice
Study: NCT00918307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Day 1 to day 3 : 0.5 mg daily ; Day 4 to day 7 : 0.5 mg twice daily ; Day 8 to week 12 : 2 x 0.5 mg twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Day 1 to day 3 : 1 pill daily ; Day 4 to day 7 : 2 pills daily ; Day 8 to week 12 : 2 pills twice daily
Study: NCT00886990

Intervention type: DRUG
Intervention: two PIs boosted by low dose ritonavir or one PI plus full dose ritonavir
Description: two PIs boosted by low dose ritonavir or one PI plus full dose ritonavir
Study: NCT04223466

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subxiphoid surgery procedure
Description: Subxiphoid procedure for thymectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: VATS surgery procedure
Description: VATS procedure for thymectomy
Study: NCT01591330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2140023 Reference form
Description: 80-mg tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2140023 Test-Low
Description: 80-mg tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2140023 Test-Medium
Description: 80-mg tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2140023 Test-High
Description: 80-mg tablet administered orally
Study: NCT02403271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: BTK Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: BTK Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Anti PDL-1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Anti PDL-1
Study: NCT01508897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Single dose administered as subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Single dose administered as subcutaneous injection
Study: NCT02197637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORAL VINORELBINE
Description: Orally vinorelbine 60 mg/m2 D1, 8 and 15 Cycle of 28 days For a maximum of 12 cycles The dose of vinorelbine should be increased to 80 mg/m2 from the 2nd cycle If on D8 and D15, the administration conditions are not met, the administration is canceled and not delayed.
Study: NCT02520479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P-CHOP
Description: Two cycles of P-CHOP:cyclophosphamide, 750 mg/m2 day 1; vincristine,(maximal dose 2 mg),adriamycin , 50 mg/m2 day 1; dexamethasone,10mg days 1-8; Pegaspargase, 2500IU/m2 day 1 are given before radiotherapy
Study: NCT02871427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nelotanserin
Description: Once Daily, Oral, at 20, 40, 60, or 80 mg dose
Study: NCT02520479

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy was scheduled after 2 cycles of P-CHOPregimen. Involved field radiotherapy(IFRT) is delivered using 6-Million electron Volts linear accelerator using 3-dimensional conformable treatment planning. The IFRT dose was 56 grays (Gy) in 28 fractions.
Study: NCT01476072

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: MRI scan
Description: MRI scan only, methodology study with no other intervention
Study: NCT03976128

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nordic Walking Training
Description: The excursions will take place predominantly in flat pathways, beginning in a local park and progressing to roadside footpaths. Each session will last an hour including a warm up, NW and a cool down with stretching exercises.
Study: NCT03313661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabergoline
Description: cabergoline 0.5 mg twice weekly within 2 hrs of awakening plus gliclazide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gliclazide
Description: gliclazide (60-120 mg)
Study: NCT03239665

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacist-led Intervention (PHARM)
Description: 60 minute didactic lecture about vaccinations.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-led Intervention (PEER)
Description: 60 minute peer led small group intervention including skits and other educational material
Study: NCT05084729

Intervention type: DEVICE
Intervention: Imagio OA/US
Description: Imagio optoacoustic
Study: NCT02520479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P-CHOP
Description: Two consolidation cycles of P-CHOP are given after radiotherapy
Study: NCT00752986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD6474 (Vandetanib at the dose of 100 mg)
Description: 100 mg as a once daily oral dose, from Day 1 UNTIL disease progression or unacceptable toxicity or consent withdrawal whichever occurs first

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match ZD6474 (Vandetanib at the dose of 100 mg)
Description: Placebo of 300 mg as a once daily oral dose, from Day 1 UNTIL disease progression or unacceptable toxicity or consent withdrawal whichever occurs first

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match ZD6474 (Vandetanib at the dose of 100 mg)
Description: Placebo of 300 mg as a once daily oral dose, from Day 1 UNTIL disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
Study: NCT04444050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986331
Description: Specified dose on specified days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo, Matching BMS-986331
Description: Specified dose on specified days
Study: NCT03976128

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional endurance training
Description: 15 minutes of Treadmill training with progressive increase of velocity followed by 20 minutes of cycloergometer with progressive increase of resistance. Each session will last an hour including a warm up, training with treadmill and cycloergometer and a cool down with stretching exercises.
Study: NCT01180777

Intervention type: DEVICE
Group type: OTHER
Intervention: etafilcon A (A)
Description: Daily wear contact lens

Intervention type: DEVICE
Group type: OTHER
Intervention: etafilcon A (A)
Description: Daily wear contact lens

Intervention type: DEVICE
Group type: OTHER
Intervention: etafilcon A (A)
Description: Daily wear contact lens

Intervention type: DEVICE
Group type: OTHER
Intervention: etafilcon A (A)
Description: Daily wear contact lens

Intervention type: DEVICE
Group type: OTHER
Intervention: etafilcon A (A)
Description: Daily wear contact lens

Intervention type: DEVICE
Group type: OTHER
Intervention: etafilcon A (A)
Description: Daily wear contact lens

Intervention type: DEVICE
Group type: OTHER
Intervention: etafilcon A (B)
Description: Daily wear contact lens

Intervention type: DEVICE
Group type: OTHER
Intervention: etafilcon A (B)
Description: Daily wear contact lens

Intervention type: DEVICE
Group type: OTHER
Intervention: etafilcon A (B)
Description: Daily wear contact lens

Intervention type: DEVICE
Group type: OTHER
Intervention: etafilcon A (B)
Description: Daily wear contact lens

Intervention type: DEVICE
Group type: OTHER
Intervention: etafilcon A (B)
Description: Daily wear contact lens

Intervention type: DEVICE
Group type: OTHER
Intervention: etafilcon A (B)
Description: Daily wear contact lens

Intervention type: DEVICE
Group type: OTHER
Intervention: etafilcon A (C)
Description: Daily wear contact lens

Intervention type: DEVICE
Group type: OTHER
Intervention: etafilcon A (C)
Description: Daily wear contact lens

Intervention type: DEVICE
Group type: OTHER
Intervention: etafilcon A (C)
Description: Daily wear contact lens

Intervention type: DEVICE
Group type: OTHER
Intervention: etafilcon A (C)
Description: Daily wear contact lens

Intervention type: DEVICE
Group type: OTHER
Intervention: etafilcon A (C)
Description: Daily wear contact lens

Intervention type: DEVICE
Group type: OTHER
Intervention: etafilcon A (C)
Description: Daily wear contact lens
Study: NCT03358953

Intervention type: DEVICE
Group type: OTHER
Intervention: Electron Cigarette
Description: Blended Tobacco flavour, 18mg/ml

Intervention type: DEVICE
Group type: OTHER
Intervention: Nicotine Replacement Patch
Description: NiQuitin 21mg
Study: NCT04115059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Oral, daily, dosing per protocol, once a day for cycle
Study: NCT02022930

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hydros

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hydros-TA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Study: NCT02602951

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilot MRI program
Description: Pilot MRI program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI with 4D Flow sequence
Description: MRI with 4D Flow sequence
Study: NCT02292225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPI-145 (duvelisib)
Description: 25mg and/or 5mg oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: 1000mg/40mL single-use vials
Study: NCT03188471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH antagonist
Description: GnRH antagonist 0.25mg daily from the day of oocyte retrieval for seven days for high risk of ovarian hyper stimulation syndrome patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin
Description: aspirin (100 mg daily, plus saline as placebo of GnRH antagonist ) for seven days
Study: NCT03150186

Intervention type: OTHER
Intervention: SHS exposure in homes
Description: The investigators will recruit 20 non-smoking volunteers living in different homes with at least one smoker: 10 participants living in more deprived neighborhoods and 10 participants living in wealthier neighborhoods. Nicotine vapor phase will be measured using passive SHS samplers. The investigators will contact with participants and make an arrangement for measuring levels of nicotine at homes. First, the investigators will hang up a passive sampler in the main room of the house in accordance with the written protocol of sample collection. One week later, the investigators will come back to the house in a second visit to remove the sample. During the second visit the investigators will administer a specific questionnaire about environmental tobacco exposure to the participant.

Intervention type: OTHER
Intervention: SHS exposure in private cars
Description: The investigators will measure levels of nicotine in 30 cars (two samples per car) in 2 European countries with different smoke-free legislation (Spain and UK). A convenience sampling will be performed considering feasibility. The investigators will recruit 30 drivers: 10 daily-smoking volunteers that usually smoke within their car; 10 daily-smoking volunteers that do not smoke within their car; and 10 non-smoking volunteers. To be eligible, participants have to spend a minimum of 30 minutes per day within the car. Nicotine vapor phase will be measured using passive SHS samplers. Two samplers will be hung up in each car during a period of 24 hours. One sampler will be open during the 24-hour sampling period. The other sampler will be only open during travelling time.

Intervention type: OTHER
Intervention: SHS exposure in outdoor settings
Description: In three types of outdoor settings (children playgrounds, terraces of hospitality venues, and entrances of primary school buildings), nicotine vapor phase will be measured using active SHS samplers. For each country, a convenience sampling of 60 outdoor settings (20 of each of the above mentioned settings) will be performed. Data collection will be conducted from March to October. The measurements will be able to be taken at any time of day providing that there are at least five adults. The investigators will collect nicotine samples using samplers attached to an air pump. Measurements will last 30 minutes. While measurements are being taken, data collectors will also conduct observations in accordance with the protocol of active sampling collection.
Study: NCT00752986

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fulvestrant
Description: All patients will receive fulvestrant Loading Dose (LD). The Loading Dose regimen is 500mg (2 injections) at day 1, followed by 250mg at day 14, 28 and every 28 days thereafter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: All patients will receive fulvestrant Loading Dose (LD). The Loading Dose regimen is 500mg (2 injections) at day 1, followed by 250mg at day 14, 28 and every 28 days thereafter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: All patients will receive fulvestrant Loading Dose (LD). The Loading Dose regimen is 500mg (2 injections) at day 1, followed by 250mg at day 14, 28 and every 28 days thereafter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD6474 (Vandetanib at the dose of 300 mg)
Description: 300 mg as a once daily oral dose, from Day 1 UNTIL disease progression or unacceptable toxicity or consent withdrawal whichever occurs first.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match ZD6474 (Vandetanib at the dose of 300 mg)
Description: Placebo of 100 mg as a once daily oral dose, from Day 1 UNTIL disease progression or unacceptable toxicity or consent withdrawal whichever occurs first

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match ZD6474 (Vandetanib at the dose of 300 mg)
Description: Placebo of 100 mg as a once daily oral dose, from Day 1 UNTIL disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
Study: NCT01525758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SI000413
Description: 1 Tablet = 200mg, (400mg, 600mg or 800mg vs. placebo) for 8weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SI000413
Description: 1 Tablet = 200mg, (400mg, 600mg or 800mg vs. placebo) for 8weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SI000413
Description: 1 Tablet = 200mg, (400mg, 600mg or 800mg vs. placebo) for 8weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: microcrystalline cellulose
Description: identical number of tablets to active drug groups
Study: NCT00843570

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nafarelin acetate, Oestradiol Valerate, Progesterone
Description: Nafarelin acetate, Nasal spray, 400 mcg b.d., 4 weeks Oestradiol Valerate, tablet, 2mg o.d day 1-5, 2mg b.d. day 6-9, 2mg t.d.s day 10-13 (step-up protocol), 2mg q.d.s (if pregnancy confirmed, 4-10 weeks Progesterone, pessary, 200mg b.d. and t.d.s. (if pregnancy confirmed), 2-10 weeks
Study: NCT00947349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin (RBV)
Description: ribavirin (RBV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated interferon (PegIFN) alfa-2a
Description: pegylated interferon (PegIFN) alfa-2a

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated interferon (PegIFN) alfa-2a
Description: pegylated interferon (PegIFN) alfa-2a

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin (RBV)
Description: ribavirin (RBV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335 NA low placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated interferon (PegIFN) alfa-2a
Description: pegylated interferon (PegIFN) alfa-2a

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin (RBV)
Description: ribavirin (RBV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335 NA high
Description: BI 201335 NA high

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335 NA low
Description: BI 201335 NA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335 NA high placebo
Description: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335 NA high
Description: BI 201335 NA high

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00291343

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tritanrix™- HepB
Description: One intramuscular dose during the booster vaccination study in subjects aged 15 to 24 months

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tritanrix™- HepB
Description: One intramuscular dose during the booster vaccination study in subjects aged 15 to 24 months

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hiberix™
Description: One intramuscular dose during the booster vaccination study in subjects aged 15 to 24 months